文献速递胸部肿瘤放疗放疗物理与技术

III期非小细胞肺癌同步放化疗联合SBRT的I期混合试验安全性报告

Simultaneous concurrent chemoradiation and SBRT in stage III NSCLC: Safety report of the phase I hybrid trial.
PubMed 文献 · Radiother Oncol · 2026-05-14

I期Hybrid试验前瞻性纳入15例III期非小细胞肺癌(NSCLC)患者,原发灶位于外周且小于5 cm,采用同步每日低剂量放化疗,混合分割方案为24次常规分割放疗联合3次SBRT,同步顺铂化疗,并采用TITE-CRM方法在14至18 Gy/次间调整SBRT分次剂量以递增平均肺剂量(MLD)。所有患者均按方案完成计划和治疗,未观察到剂量限制性毒性,最高治疗MLD为19.1 Gy;最常见1-2级毒性为放射性肺炎(7例)和肋骨骨折(6例),未观察到3级及以上肺或纵隔毒性。局部和区域控制率均达93%,但11例(73%)患者在中位11个月时出现远处进展。结论认为该方案可行且安全,局部区域控制率高。

要点

  • 15例III期NSCLC患者按方案完成同步SBRT联合常规分割放疗及顺铂化疗,未观察到剂量限制性毒性。
  • 最高治疗MLD达19.1 Gy,未出现3级及以上肺或纵隔毒性。
  • 局部和区域控制率均为93%,但73%患者在中位11个月出现远处进展。

核心结论

  • 同步原发灶SBRT联合淋巴结常规分割放疗并同步每日顺铂化疗可行且安全,局部区域控制率高。

研究设计与样本

  • I期Hybrid试验前瞻性纳入15例III期NSCLC患者,原发灶位于外周且小于5 cm。
  • 采用混合分割方案:同步24次常规分割放疗联合3次SBRT,同步每日低剂量顺铂化疗。
  • 采用TITE-CRM方法在14至18 Gy/次间调整SBRT分次剂量以递增允许的平均肺剂量(MLD)。

主要发现

  • 所有患者均能按方案完成计划和治疗。
  • 未观察到剂量限制性毒性,最高治疗MLD为19.1 Gy。
  • 最常见1-2级毒性为放射性肺炎(7例)和肋骨骨折(6例),未观察到3级及以上肺或纵隔毒性。
  • 局部和区域控制率均为93%,但11例(73%)患者在中位11个月时出现远处进展。

关键数值与推荐

  • SBRT分次剂量在14至18 Gy/次之间调整,最高治疗MLD为19.1 Gy。
  • 局部控制率和区域控制率均为93%。
  • 11例(73%)患者在中位11个月出现远处进展。

临床怎么用

  • 对于外周型原发灶小于5 cm的III期NSCLC,可考虑同步原发灶SBRT联合淋巴结常规分割放疗及同步顺铂化疗。
  • 治疗中需关注放射性肺炎和肋骨骨折等1-2级毒性。
  • 尽管局部区域控制率高,仍需警惕远处进展,中位11个月时73%患者出现远处进展。

局限性

  • I期试验样本量小(15例),安全性结论需更大样本验证。
  • 随访中远处进展发生率高,提示需进一步评估远处控制策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The phase I Hybrid trial assessed the safety of combining simultaneous stereotactic body radiotherapy (SBRT) to the primary tumor and fractionated radiotherapy to the lymph nodes with concurrent cisplatin. MATERIALS AND METHODS: 15 patients with stage III non-small cell lung cancer (NSCLC) with a peripheral primary tumor <5 cm were prospectively included and treated with concurrent daily low-dose chemoradiation using a hybrid fractionation schedule of simultaneous 24 fractions conventionally fractionated radiotherapy and 3 fractions SBRT. The allowed mean lung dose (MLD) was escalated by adapting the SBRT fraction dose between 14 and 18 Gy per fraction using the time-to-event continual reassessment method (TITE-CRM). RESULTS: All patients were able to be planned and treated per protocol. No dose-limiting toxicity was observed with a maximum treated MLD of 19.1 Gy. The most common Grade 1-2 toxicities consisted of radiation pneumonitis (N = 7) or rib fractures (N = 6). No G3+ pulmonary or mediastinal toxicities were observed. Although local and regional control were excellent (both 93%), 11 patients (73%) eventually developed progressive disease at distant sites at a median of 11 months. CONCLUSION: Simultaneous SBRT to the primary tumor and fractionated radiotherapy to the lymph nodes is feasible and safe with concurrent daily dose cisplatin with high loco-regional control rates.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. de Jong MC, Hope AJ, Belderbos JSA, et al. Simultaneous concurrent chemoradiation and SBRT in stage III NSCLC: Safety report of the phase I hybrid trial. Radiother Oncol. 2026. PMID: 42134663. doi:10.1016/j.radonc.2026.111551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。